Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival

Neoadjuvant therapy has been increasingly used to treat patients with potentially resectable pancreatic ductal adenocarcinoma (PDAC). Although the College of American Pathologists (CAP) grading scheme for tumor response in posttherapy specimens has been used, its clinical significance has not been v...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American journal of surgical pathology 2016-12, Vol.40 (12), p.1653-1660
Hauptverfasser:	Lee, Sun Mi, Katz, Matthew H.G, Liu, Li, Sundar, Manonmani, Wang, Hua, Varadhachary, Gauri R, Wolff, Robert A, Lee, Jeffrey E, Maitra, Anirban, Fleming, Jason B, Rashid, Asif, Wang, Huamin
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Carcinoma, Pancreatic Ductal - mortality Carcinoma, Pancreatic Ductal - pathology Carcinoma, Pancreatic Ductal - therapy Chemoradiotherapy, Adjuvant Female Follow-Up Studies Humans Lymphatic Metastasis Male Middle Aged Neoadjuvant Therapy Neoplasm Grading Pancreatic Neoplasms - mortality Pancreatic Neoplasms - pathology Pancreatic Neoplasms - therapy Pancreaticoduodenectomy Prognosis Retrospective Studies Survival Analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Neoadjuvant therapy has been increasingly used to treat patients with potentially resectable pancreatic ductal adenocarcinoma (PDAC). Although the College of American Pathologists (CAP) grading scheme for tumor response in posttherapy specimens has been used, its clinical significance has not been validated. Previously, we proposed a 3-tier histologic tumor regression grading (HTRG) scheme (HTRG 0, no viable tumor; HTRG 1,
ISSN:	0147-5185 1532-0979
DOI:	10.1097/PAS.0000000000000738